All In Biotech

NDA 050162 · Pfizer

Cleocin Hydrochloride

Clindamycin Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1970

Feb 22, 1970

Approved uses

4

Original approval plus efficacy supplements

Registered trials

274

66 Phase 3, 28 recruiting

FAERS reports

3,695

2,818 serious, 243 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING Clostridioides difficile infection (CDI) has been reported with use of nearly all antibacterial agents, including CLEOCIN HCl and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile. Because CLEOCIN HCl therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. C. difficile produces toxins A and B, which contribute to the development of CDI. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy...

What it is approved for

From the label in effect Sep 16, 2026.

INDICATIONS AND USAGE Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN HCl and other antibacterial drugs, CLEOCIN HCl should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and...

Mechanism: Mechanism of Action Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is bacteriostatic.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 14, 1988 Supplement 11 · Efficacy
  • Nov 3, 1981 Supplement 76 · Efficacy
  • May 22, 1970 Supplement 1 · Efficacy
  • Feb 22, 1970 Original approval
3 products under this application
  • CLEOCIN HYDROCHLORIDE · CLINDAMYCIN HYDROCHLORIDE EQ 300MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • CLEOCIN HYDROCHLORIDE · CLINDAMYCIN HYDROCHLORIDE EQ 75MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • CLEOCIN HYDROCHLORIDE · CLINDAMYCIN HYDROCHLORIDE EQ 150MG BASE · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Clindamycin" as an intervention, any sponsor and status, largest first.

All 274 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea293
  • rash278
  • nausea258
  • off label use257
  • pain232
  • dyspnoea212
  • drug ineffective211
  • drug hypersensitivity197
  • headache181
  • pruritus179
  • fatigue168
  • arthralgia158

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200434
200580
200652
200743
200855
200950
201044
201161
201291
201340
201428
201551
2016123
201783
2018105
2019153
2020173
2021224
2022444
2023440
2024537
2025462
2026322

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Feb 25, 2026

    Cleocin Hydrochloride, Capsule, 75 mg (NDC 0009-0331-02). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Feb 25, 2026

    Cleocin Hydrochloride, Capsule, 150 mg (NDC 0009-0225-02). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Feb 25, 2026

    Cleocin Hydrochloride, Capsule, 300 mg (NDC 0009-0395-14). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,207 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.